Logo image of IVN.MI

IVISION TECH SPA (IVN.MI) Stock Fundamental Analysis

BIT:IVN - Euronext Milan - IT0005554784 - Common Stock - Currency: EUR

2.32  -0.05 (-2.11%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IVN. IVN was compared to 65 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of IVN have multiple concerns. IVN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year IVN has reported negative net income.
IVN had a positive operating cash flow in the past year.
IVN.MI Yearly Net Income VS EBIT VS OCF VS FCFIVN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 2M -2M -4M

1.2 Ratios

IVN has a Return On Assets of -0.04%. This is in the lower half of the industry: IVN underperforms 63.08% of its industry peers.
IVN has a Return On Equity of -0.13%. This is in the lower half of the industry: IVN underperforms 63.08% of its industry peers.
IVN has a worse Return On Invested Capital (2.67%) than 64.62% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IVN is below the industry average of 8.65%.
Industry RankSector Rank
ROA -0.04%
ROE -0.13%
ROIC 2.67%
ROA(3y)0.84%
ROA(5y)N/A
ROE(3y)3%
ROE(5y)N/A
ROIC(3y)4%
ROIC(5y)N/A
IVN.MI Yearly ROA, ROE, ROICIVN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 2 4 6

1.3 Margins

IVN has a Operating Margin of 6.07%. This is comparable to the rest of the industry: IVN outperforms 44.62% of its industry peers.
IVN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 60.19%, IVN is in line with its industry, outperforming 52.31% of the companies in the same industry.
In the last couple of years the Gross Margin of IVN has declined.
Industry RankSector Rank
OM 6.07%
PM (TTM) N/A
GM 60.19%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.35%
GM growth 5YN/A
IVN.MI Yearly Profit, Operating, Gross MarginsIVN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 40 60 80

3

2. Health

2.1 Basic Checks

IVN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
IVN has more shares outstanding than it did 1 year ago.
Compared to 1 year ago, IVN has an improved debt to assets ratio.
IVN.MI Yearly Shares OutstandingIVN.MI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2M 4M 6M
IVN.MI Yearly Total Debt VS Total AssetsIVN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 1.37, we must say that IVN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.37, IVN is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
IVN has a debt to FCF ratio of 14.80. This is a negative value and a sign of low solvency as IVN would need 14.80 years to pay back of all of its debts.
The Debt to FCF ratio of IVN (14.80) is comparable to the rest of the industry.
IVN has a Debt/Equity ratio of 0.78. This is a neutral value indicating IVN is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.78, IVN is not doing good in the industry: 75.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 14.8
Altman-Z 1.37
ROIC/WACC0.37
WACC7.28%
IVN.MI Yearly LT Debt VS Equity VS FCFIVN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M

2.3 Liquidity

IVN has a Current Ratio of 1.93. This is a normal value and indicates that IVN is financially healthy and should not expect problems in meeting its short term obligations.
IVN has a Current ratio (1.93) which is comparable to the rest of the industry.
IVN has a Quick Ratio of 1.31. This is a normal value and indicates that IVN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IVN (1.31) is better than 64.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.93
Quick Ratio 1.31
IVN.MI Yearly Current Assets VS Current LiabilitesIVN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

3

3. Growth

3.1 Past

The earnings per share for IVN have decreased strongly by -108.76% in the last year.
The Revenue has grown by 61.65% in the past year. This is a very strong growth!
IVN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 87.46% yearly.
EPS 1Y (TTM)-108.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)61.65%
Revenue growth 3Y87.46%
Revenue growth 5YN/A
Sales Q2Q%96.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IVN.MI Yearly Revenue VS EstimatesIVN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 5M 10M 15M

2

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
IVN.MI Price Earnings VS Forward Price EarningsIVN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

87.69% of the companies in the same industry are more expensive than IVN, based on the Enterprise Value to EBITDA ratio.
73.85% of the companies in the same industry are more expensive than IVN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 25.28
EV/EBITDA 8.07
IVN.MI Per share dataIVN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

IVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

IVISION TECH SPA

BIT:IVN (6/6/2025, 7:00:00 PM)

2.32

-0.05 (-2.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners1.12%
Inst Owner ChangeN/A
Ins Owners66.68%
Ins Owner ChangeN/A
Market Cap18.10M
Analysts80
Price Target3.37 (45.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.18
P/FCF 25.28
P/OCF 5.53
P/B 1.85
P/tB 3.08
EV/EBITDA 8.07
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.09
FCFY3.96%
OCF(TTM)0.42
OCFY18.08%
SpS1.97
BVpS1.25
TBVpS0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.04%
ROE -0.13%
ROCE 3.69%
ROIC 2.67%
ROICexc 3.12%
ROICexgc 3.8%
OM 6.07%
PM (TTM) N/A
GM 60.19%
FCFM 4.66%
ROA(3y)0.84%
ROA(5y)N/A
ROE(3y)3%
ROE(5y)N/A
ROIC(3y)4%
ROIC(5y)N/A
ROICexc(3y)4.55%
ROICexc(5y)N/A
ROICexgc(3y)5.61%
ROICexgc(5y)N/A
ROCE(3y)5.53%
ROCE(5y)N/A
ROICexcg growth 3Y-9.79%
ROICexcg growth 5YN/A
ROICexc growth 3Y-13.26%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.35%
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 14.8
Debt/EBITDA 2.46
Cap/Depr 117.97%
Cap/Sales 16.64%
Interest Coverage 250
Cash Conversion 105.58%
Profit Quality N/A
Current Ratio 1.93
Quick Ratio 1.31
Altman-Z 1.37
F-Score4
WACC7.28%
ROIC/WACC0.37
Cap/Depr(3y)136.09%
Cap/Depr(5y)N/A
Cap/Sales(3y)20.44%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-108.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)61.65%
Revenue growth 3Y87.46%
Revenue growth 5YN/A
Sales Q2Q%96.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.34%
EBIT growth 3Y23.59%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y137.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y297.1%
OCF growth 3YN/A
OCF growth 5YN/A